CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
提高 CAR-T 细胞治疗的安全性：接受 CAR-T 细胞治疗的复发/难治性 B 细胞淋巴瘤患者病毒感染的风险与预防
英文原题：Improving the safety of CAR-T-cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B-cell lymphoma undergoing CAR-T-cell therapy.
查看英文原题
Improving the safety of CAR-T-cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B-cell lymphoma undergoing CAR-T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法是一种针对复发/难治性B细胞淋巴瘤的创新免疫治疗，但因频繁的病毒感染而面临挑战。尽管如此，目前明显缺乏针对风险评估、监测和治疗管理的全面综述。本综述阐明了CAR-T 受者病毒感染期间免疫应答受损的机制，汇总了易感性危险因素，并探讨了预防策略。在以Omicron变异株为标志的后疫情时代，CAR-T 疗法面临新的严重威胁，有必要探索COVID-19的预防和治疗措施。总体而言，本综述为病毒感染的预防和管理提供了建议，以提高CAR-T 产品的安全性和受者的生存率。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy, an innovative immunotherapeutic against relapsed/refractory B-cell lymphoma, faces challenges due to frequent viral infections. Despite this, a comprehensive review addressing risk assessment, surveillance, and treatment management is notably absent.
This review elucidates immune response compromises during viral infections in CAR-T recipients, collates susceptibility risk factors, and deliberates on preventive strategies. In the post-pandemic era, marked by the Omicron variant, new and severe threats to CAR-T therapy emerge, necessitating exploration of preventive and treatment measures for COVID-19.
Overall, the review provides recommendations for viral infection prophylaxis and management, enhancing CAR-T product safety and recipient survival.
论文信息
- 作者
- Qian H、Yang X、Zhang T、Zou P、Zhang Y、Tian W、Mao Z、Wei J
- 单位
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- American journal of hematology2024 Apr
- 原文标识
- PubMed 38197307 · DOI 10.1002/ajh.27198